RENO, Nev., June 14, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) references new research which suggests the active ingredient found in Martin Nutraceuticals' Oxygenol(tm), Pine Bark Extract may help young women suffering from asthma.
The rate of asthma continues to steadily increase world-wide, however young women may be particularly susceptible, according to a recent study presented to the American Thoracic Society by Swedish Researchers.
Dr. A.W. Martin DC, Ph.D., RNCP, DNM, Director of research at Martin Nutraceuticals, notes that there appears to be an all natural ingredient found in their proprietary formula Oxygenol(tm) that is showing tremendous promise in the treatment of asthma. In a double blind placebo study published in Nov/Dec 2004 issue of journal of asthma found that 60 children aged 6-18 were able to significantly reduce or discontinue their use of rescue inhalers with Pine Bark Extract, more specifically Pycnogenol(r), more often than the placebo group.
Martin's Oxygenol(tm) main active ingredient is a proprietary blend of pine bark that is even higher in anti-oxidant value than Pycnogenol(r).
"Pine Bark anti-inflammatory activity has impressed me time and time again and I am now confident in prescribing Oxygenol(tm) for my asthma patients," states Dr. Martin. Oxygenol(tm) combines the Pine Bark Extract with a high dose of all natural vitamin C and an enzyme to further the effectiveness of this product with the treatment of Asthma.
"Oxygenol(tm) is truly a fantastic product that shows great ancillary benefits with daily use. We are very excited about getting this wonderful product to the market place," continues Dr. Martin.
Dr. Martin is the author of the acclaimed book "Pycnogenol, the Bark with the Bite" and accomplished his Ph.D. thesis on Pycnogenol(r) and its effects on Chronic Fatigue Syndrome.
Oxygenol(tm) will be available at fine retail stores, shortly.
Forward Looking Statements
This release includes forward-looking statements and projections, made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, including, without limitation, the ability to implement and achieve our objectives in the long-range plan; actions by the credit rating agencies; the successful close of our financing transactions; our ability to divest of certain assets; inability to realize anticipated synergies and cost savings associated with restructurings and divestitures on a timely basis; the uncertainties associated with governmental regulation; the uncertainties associated with the outcome of governmental investigations; the outcome of pending litigation including shareholder derivative and class actions; difficulty in integration of the operations of previously acquired companies, and competition. While the company makes these statements and projections in good faith, neither the company nor its management can guarantee that anticipated future results will be achieved. The company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.